{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:13:49Z","timestamp":1787004829575,"version":"build-2736575974"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1053\/j.seminoncol.2010.10.002","type":"journal-article","created":{"date-parts":[[2010,11,25]],"date-time":"2010-11-25T04:48:26Z","timestamp":1290660506000},"page":"S15-S29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"special_numbering":"S2","title":["Implications of Bone Metastases and the Benefits of Bone-Targeted Therapy"],"prefix":"10.1053","volume":"37","author":[{"given":"Allan","family":"Lipton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2010.10.002_bib1","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib2","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"10.1053\/j.seminoncol.2010.10.002_bib3","doi-asserted-by":"crossref","first-page":"6305s","DOI":"10.1158\/1078-0432.CCR-06-1157","article-title":"Future treatment of bone metastases","volume":"12","author":"Lipton","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2217\/fon.09.138","article-title":"Emerging therapeutic targets in breast cancer bone metastasis","volume":"6","author":"Rose","year":"2010","journal-title":"Future Oncol"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib5","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.1073\/pnas.0601643103","article-title":"The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs","volume":"103","author":"Kavanagh","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib6","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2796.1999.00507.x","article-title":"Oral clodronate in breast cancer patients with bone metastases: a randomized study","volume":"246","author":"Kristensen","year":"1999","journal-title":"J Intern Med"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib9","first-page":"701","article-title":"[Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases]","volume":"88","author":"Tubiana-Hulin","year":"2001","journal-title":"Bull Cancer"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib10","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1200\/JCO.1996.14.9.2552","article-title":"Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial","volume":"14","author":"Conte","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib11","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","article-title":"Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate","volume":"16","author":"Hortobagyi","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib12","first-page":"3383","article-title":"Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study","volume":"19","author":"Hultborn","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib13","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","article-title":"Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial","volume":"17","author":"Theriault","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib14","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib15","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib16","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","article-title":"Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies","volume":"90","author":"Body","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib17","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","article-title":"Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib19","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/1078-0432.CCR-05-1933","article-title":"A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer","volume":"12","author":"Body","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"suppl 24","key":"10.1053\/j.seminoncol.2010.10.002_bib20","article-title":"A comparison of denosumab versus zoledronic acid for the prevention of skeletal-related events in breast cancer patients with bone metastases [abstract]","volume":"69","author":"Stopeck","year":"2009","journal-title":"Cancer Res"},{"issue":"Suppl 4","key":"10.1053\/j.seminoncol.2010.10.002_bib21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.9-90004-14","article-title":"Bisphosphonates: clinical experience","volume":"9","author":"Coleman","year":"2004","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib22","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1002\/1097-0142(19941201)74:11<2949::AID-CNCR2820741110>3.0.CO;2-Q","article-title":"Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer","volume":"74","author":"Glover","year":"1994","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib23","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/bjc.1988.272","article-title":"Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD)","volume":"58","author":"Coleman","year":"1988","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib24","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/bmj.297.6651.772","article-title":"Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma","volume":"297","author":"Morton","year":"1988","journal-title":"BMJ"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib25","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/978-3-642-83668-8_5","article-title":"Treatment of tumor-induced osteolysis by APD","volume":"116","author":"Burckhardt","year":"1989","journal-title":"Recent Results Cancer Res"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1053\/j.seminoncol.2004.07.025","article-title":"Ibandronate reduces skeletal morbidity in patients with breast cancer","volume":"31","author":"Tripathy","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib27","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0885-3924(97)00075-4","article-title":"A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain","volume":"13","author":"Ernst","year":"1997","journal-title":"J Pain Symptom Manage"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib28","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF02549644","article-title":"Effect of oral clodronate on bone pain","volume":"24","author":"Elomaa","year":"1992","journal-title":"Int Urol Nephrol"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib29","first-page":"4717","article-title":"The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer","volume":"17","author":"Strang","year":"1997","journal-title":"Anticancer Res"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib30","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/bjc.1997.488","article-title":"Concomitant i.v. and oral clodronate in the relief of bone pain\u2014a double-blind placebo-controlled study in patients with prostate cancer","volume":"76","author":"Kylmala","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib31","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1200\/JCO.2003.03.042","article-title":"Randomized, double-blind, controlled trial of mitoxantrone\/prednisone and clodronate versus mitoxantrone\/prednisone and placebo in patients with hormone-refractory prostate cancer and pain","volume":"21","author":"Ernst","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib32","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/jnci\/djg038","article-title":"A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial)","volume":"95","author":"Dearnaley","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib33","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1200\/JCO.2003.05.147","article-title":"Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer","volume":"21","author":"Small","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib34","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib35","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.juro.2009.04.023","article-title":"Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial","volume":"182","author":"Fizazi","year":"2009","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib36","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1200\/JCO.2003.04.176","article-title":"Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial","volume":"21","author":"Carducci","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib37","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/cncr.22996","article-title":"A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer","volume":"110","author":"Carducci","year":"2007","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib38","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/cncr.23864","article-title":"Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer","volume":"113","author":"Nelson","year":"2008","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib39","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.eururo.2008.11.002","article-title":"Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial","volume":"55","author":"James","year":"2009","journal-title":"Eur Urol"},{"issue":"suppl 15","key":"10.1053\/j.seminoncol.2010.10.002_bib40","article-title":"Circulating tumor cells capture and analysis in a multicenter SWOG-coordinated prostate cancer trial [abstract]","volume":"28","author":"Goldkorn","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib41","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","article-title":"Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma","volume":"340","author":"Lahtinen","year":"1992","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib42","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma","volume":"100","author":"McCloskey","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib43","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1365-2141.2001.02851.x","article-title":"Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma","volume":"113","author":"McCloskey","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib44","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events","volume":"16","author":"Berenson","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib45","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1046\/j.1365-2141.1998.00695.x","article-title":"Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial","volume":"101","author":"Brincker","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib46","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/S1359-6349(09)72055-5","article-title":"A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma [abstract]","volume":"7","author":"Henry","year":"2009","journal-title":"Eur J Cancer Suppl"},{"issue":"suppl 15","key":"10.1053\/j.seminoncol.2010.10.002_bib48","article-title":"Denosumab in the treatment of bone metastases from advanced cancer or multiple myeloma (MM): Analyses from a phase III randomized trial [abstract]","volume":"28","author":"Vadhan-Raj","year":"2010","journal-title":"J Clin Oncol"},{"issue":"suppl 15S","key":"10.1053\/j.seminoncol.2010.10.002_bib49","article-title":"Effects of denosumab versus zoledronic acid (ZA) on pain in patients (pts) with advanced cancer (excluding breast and prostate) or multiple myeloma (MM): Results from a randomized phase III clinical trial [abstract]","volume":"28","author":"van Moos","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib50","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.749.749","article-title":"ACE-011, a soluble activin receptor type Iia IgG-Fc fusion protein, increases hemoglobin (Hb) and improves bone lesions in multiple myeloma patients receiving myelosuppressive chemotherapy [abstract]","volume":"114","author":"Abdulkadyrov","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib51","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib52","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ajh.21509","article-title":"An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma","volume":"84","author":"Vij","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib53","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1359\/jbmr.081208","article-title":"Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women","volume":"24","author":"Ruckle","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib54","doi-asserted-by":"crossref","unstructured":"Kim KT, Borgstein NG, Yang Y, et al. ACE-011, a soluble activin receptor type IIa IgG-Fc fusion protein, increases hemoglobin and hematocrit levels in postmenopausal healthy women. 50th American Society of Hematology Annual Meeting and Exposition, San Francisco, CA, December 6\u20139, 2008.","DOI":"10.1182\/blood.V112.11.3866.3866"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib55","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.750.750","article-title":"A phase I\/II study of BHQ880, a novel osteoblast activating, anti-DKK1 human monoclonal antibody, in relapsed and refractory multiple myeloma (MM) patients treated with zoledronic acid (Zol) and anti-myeloma therapy (MM Tx) [abstract]","volume":"114","author":"Padmanabhan","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib56","first-page":"129","article-title":"Clodronate and radiotherapy for the treatment of osteolysis caused by metastasis of breast carcinoma and non-small cell lung carcinoma","volume":"10","author":"Caristi","year":"1990","journal-title":"G Ital Oncol"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib57","first-page":"213","article-title":"A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy","volume":"17","author":"Piga","year":"1998","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib58","first-page":"5245","article-title":"Routine use of pamidronate in NSCLC patients with bone metastasis: results from a retrospective analysis","volume":"29","author":"Spizzo","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib59","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib60","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3816\/CLC.2004.n.030","article-title":"Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications","volume":"6","author":"Hirsh","year":"2004","journal-title":"Clin Lung Cancer"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib61","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/JTO.0b013e3181651c0e","article-title":"Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity","volume":"3","author":"Hirsh","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib62","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/ijc.24470","article-title":"The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis","volume":"125","author":"Zarogoulidis","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib63","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0093-7754(01)90232-5","article-title":"Dosing regimens and main adverse events of bisphosphonates","volume":"28","author":"Body","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/S1359-6349(09)72028-2","article-title":"Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study [abstract]","volume":"7","author":"Stopeck","year":"2009","journal-title":"Eur J Cancer Suppl"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib65","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1053\/j.seminoncol.2010.10.002_bib66","article-title":"Management of bone metastases from lung cancer: Consensus recommendations from an international panel [abstract]","volume":"20","author":"Nackaerts","year":"200826","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib67","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","article-title":"American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma","volume":"25","author":"Kyle","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.10.002_bib68","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/annonc\/mdn796","article-title":"The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network","volume":"20","author":"Terpos","year":"2009","journal-title":"Ann Oncol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775410001727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775410001727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:52:37Z","timestamp":1758804757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775410001727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":68,"alternative-id":["S0093775410001727"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2010.10.002","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implications of Bone Metastases and the Benefits of Bone-Targeted Therapy","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2010.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}